Peregrine Pharma (PPHM) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Noble Financial Keeps Peregrine Pharma (PPHM) at 'Buy' Amid Expansion of Bavituximab Immunooncology Programs
December 14, 2015 2:21 PM ESTNoble Financial affirms Peregrine Pharmaceuticals (Nasdaq: PPHM) with a Buy rating and $5 price target following Q2 results and update issued last week.
Analyst Rahul Jasuja commented on Peregrine's expansion of bavituximab immuno-oncology programs and noted the following key points:
Phase 3 SUNRISE trial comparing bavituximab + docetaxel vs... More